Taking over from the son of the company’s founder at the beginning of 2023, Martin Arès, the CEO of Canadian generics manufacturer Pharmascience, talks to Generics Bulletin about investment, international expansion and biosimilars.
“The ambition is really to double our sales in the next five to six years,” the CEO of privately owned Canadian manufacturer PharmaScience, Martin Arès, reveals to Generics Bulletin as part of an exclusive interview.
“It took 40 years to reach CAD1bn ($738m) of sales,” he reflects. “I would be very disappointed if we don’t...
Clinical-stage reformulation specialist Lipella Pharmaceuticals has insisted that “our commitment to our shareholders, our mission, and our clinical goals has not changed” after its common stock was delisted from the Nasdaq Capital Market.
Viatris has secured two positive opinions from the European Medicines Agency’s Committee for Medicinal Products for Human Use for generics to two blockbusters: Gilead’s HIV drug Odefsey and Boehringer’s IPF treatment Ofev, with a path to approvals possible in 67 days.
The AAM has welcomed a US appeals court decision backing an injunction against a Minnesota state law on drug pricing, following an earlier favorable district court ruling.
